Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Oct;24(4):415–424. doi: 10.1111/j.1365-2125.1987.tb03193.x

Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172).

D P Mikhailidis 1, V A Fonseca 1, M A Barradas 1, J Y Jeremy 1, P Dandona 1
PMCID: PMC1386302  PMID: 3689624

Abstract

1. The effects of an intravenous injection of a conventional high molecular weight heparin (HMWH) were compared with those of a low molecular weight heparinoid (Org 10172). A bolus injection of HMWH (5000 iu) was associated with: (a) a small but significant prolongation of bleeding time (BT); (b) a significant fall in PRP platelet count; (c) significantly enhanced platelet aggregation; and (d) significantly increased platelet thromboxane A2 (TXA2) release. These changes were not observed following the intravenous injection of Org 10172 (3200 anti Xa U). 2. These experiments were repeated following the oral administration of acetylsalicylic acid (ASA). HMWH again caused some enhancement of platelet aggregation despite the ASA-mediated inhibition of platelet aggregation and TXA2 release. Administration of Org 10172 to subjects taking ASA did not alter any of the platelet function indices. 3. In additional control experiments the injection of 5000 iu of HMWH was associated with a significant fall in PRP but not whole blood platelet counts. This finding suggests that the fall in PRP platelet count is a methodological artefact. 4. The HMWH also induced a significantly greater increase in serum non-esterified fatty acid (NEFA) concentrations than Org 10172. 5. The present findings indicate that Org 10172 is a less potent stimulator of platelet aggregation and lipolysis than HMWH. 6. The minor prolongation of the BT after HMWH is not compatible with enhanced aggregation but may be a consequence of alterations in the activity of coagulation factors and vascular-platelet interactions or of ongoing platelet activation accompanied by granule depletion. 7. The different effects of the two anticoagulants assessed suggests a therapeutic advantage in favour of Org 10172, especially in patients with hyperactive platelets.

Full text

PDF
415

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barradas M. A., Mikhailidis D. P., Dandona P. The effect of non-esterified fatty acids on vascular ADP-degrading enzyme activity. Diabetes Res Clin Pract. 1987 Jan-Feb;3(1):9–19. doi: 10.1016/s0168-8227(87)80003-7. [DOI] [PubMed] [Google Scholar]
  2. Brace L. D., Fareed J. An objective assessment of the interaction of heparin and its fractions with human platelets. Semin Thromb Hemost. 1985 Apr;11(2):190–198. doi: 10.1055/s-2007-1004374. [DOI] [PubMed] [Google Scholar]
  3. Brace L. D., Issleib S., Fareed J. Heparin-induced platelet aggregation is inhibited by antagonists of the thromboxane pathway. Thromb Res. 1985 Aug 15;39(4):533–539. doi: 10.1016/0049-3848(85)90176-8. [DOI] [PubMed] [Google Scholar]
  4. Eika C. On the mechanism of platelet aggregation induced by heparin, protamine and polybrene. Scand J Haematol. 1972;9(3):248–257. doi: 10.1111/j.1600-0609.1972.tb00937.x. [DOI] [PubMed] [Google Scholar]
  5. GOLLUB S., ULIN A. W. Heparin-induced thrombocytopenia in man. J Lab Clin Med. 1962 Mar;59:430–435. [PubMed] [Google Scholar]
  6. Harker L. A., Slichter S. J. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med. 1972 Jul 27;287(4):155–159. doi: 10.1056/NEJM197207272870401. [DOI] [PubMed] [Google Scholar]
  7. Heiden D., Mielke C. H., Jr, Rodvien R. Impairment by heparin of primary haemostasis and platelet [14C]5-hydroxytryptamine release. Br J Haematol. 1977 Jul;36(3):427–436. doi: 10.1111/j.1365-2141.1977.tb00666.x. [DOI] [PubMed] [Google Scholar]
  8. Ireland H., Lane D. A., Flynn A., Anastassiades E., Curtis J. R. The anticoagulant effect of heparinoid Org 10172 during haemodialysis: an objective assessment. Thromb Haemost. 1986 Apr 30;55(2):271–275. [PubMed] [Google Scholar]
  9. Jeremy J. Y., Mikhailidis D. P., Dandona P. Simulating the diabetic environment modifies in vitro prostacyclin synthesis. Diabetes. 1983 Mar;32(3):217–221. doi: 10.2337/diab.32.3.217. [DOI] [PubMed] [Google Scholar]
  10. Kakkar V. V., Djazaeri B., Fok J., Fletcher M., Scully M. F., Westwick J. Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. Br Med J (Clin Res Ed) 1982 Feb 6;284(6313):375–379. doi: 10.1136/bmj.284.6313.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kelton J. G. Heparin-induced thrombocytopenia. Haemostasis. 1986;16(2):173–186. doi: 10.1159/000215288. [DOI] [PubMed] [Google Scholar]
  12. Leroy J., Leclerc M. H., Delahousse B., Guérois C., Foloppe P., Gruel Y., Toulemonde F. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216). Semin Thromb Hemost. 1985 Jul;11(3):326–329. doi: 10.1055/s-2007-1004387. [DOI] [PubMed] [Google Scholar]
  13. Lind S. E. Prolonged bleeding time. Am J Med. 1984 Aug;77(2):305–312. doi: 10.1016/0002-9343(84)90707-1. [DOI] [PubMed] [Google Scholar]
  14. Malpass T. W., Savage B., Hanson S. R., Slichter S. J., Harker L. A. Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders. J Lab Clin Med. 1984 Jun;103(6):894–904. [PubMed] [Google Scholar]
  15. Mikhailidis D. P., Barradas M. A., Dandona P. Heparin-induced platelet aggregation is inhibited by antagonists of the thromboxane pathway. Thromb Res. 1986 Jun 1;42(5):719–720. doi: 10.1016/0049-3848(86)90353-1. [DOI] [PubMed] [Google Scholar]
  16. Mikhailidis D. P., Barradas M. A., Hutton R. A., Jeremy J. Y., Sabur M., Dandona P. The effect of non-specific beta-blockade on metabolic and haemostatic variables during hypoglycaemia. Diabetes Res. 1985 May;2(3):127–134. [PubMed] [Google Scholar]
  17. Mikhailidis D. P., Barradas M. A., Jeremy J. Y., Gracey L., Wakeling A., Dandona P. Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease. Eur J Clin Invest. 1985 Dec;15(6):313–319. doi: 10.1111/j.1365-2362.1985.tb00278.x. [DOI] [PubMed] [Google Scholar]
  18. Mikhailidis D. P., Barradas M. A., Maris A., Jeremy J. Y., Dandona P. Fibrinogen mediated activation of platelet aggregation and thromboxane A2 release: pathological implications in vascular disease. J Clin Pathol. 1985 Oct;38(10):1166–1171. doi: 10.1136/jcp.38.10.1166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mikhailidis D. P., Barradas M. A., Mier A., Boag F., Jeremy J. Y., Havard C. W., Dandona P. Platelet function in patients admitted with a diagnosis of myocardial infarction. Angiology. 1987 Jan;38(1 Pt 1):36–45. doi: 10.1177/000331978703800105. [DOI] [PubMed] [Google Scholar]
  20. Mikhailidis D. P., Barradas M. A., Mikhailidis A. M., Magnani H., Dandona P. Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function. Br J Clin Pharmacol. 1984 Jan;17(1):43–48. doi: 10.1111/j.1365-2125.1984.tb04997.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Mikhailidis D. P., Hutton R. A. Intermittent venous sampling without heparinisation. Br Med J. 1980 Jan 12;280(6207):111–111. doi: 10.1136/bmj.280.6207.111-c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mikhailidis D. P., Jenkins W. J., Barradas M. A., Jeremy J. Y., Dandona P. Platelet function defects in chronic alcoholism. Br Med J (Clin Res Ed) 1986 Sep 20;293(6549):715–718. doi: 10.1136/bmj.293.6549.715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mikhailidis D. P., Jeremy J. Y., Barradas M. A., Green N., Dandona P. Effect of ethanol on vascular prostacyclin (prostaglandin I2) synthesis, platelet aggregation, and platelet thromboxane release. Br Med J (Clin Res Ed) 1983 Nov 19;287(6404):1495–1498. doi: 10.1136/bmj.287.6404.1495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mikhailidis D. P., Mikhailidis A. M., Barradas M. A., Dandona P. Effect of nonesterified fatty acids on the stability of prostacyclin activity. Metabolism. 1983 Jul;32(7):717–721. doi: 10.1016/0026-0495(83)90130-0. [DOI] [PubMed] [Google Scholar]
  25. Persson E., Nordenström J., Nilsson-Ehle P., Hagenfeldt L. Lipolytic and anticoagulant activities of a low molecular weight fragment of heparin. Eur J Clin Invest. 1985 Aug;15(4):215–220. doi: 10.1111/j.1365-2362.1985.tb00171.x. [DOI] [PubMed] [Google Scholar]
  26. Teien A. N., Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res. 1977 Mar;10(3):399–410. doi: 10.1016/0049-3848(77)90150-5. [DOI] [PubMed] [Google Scholar]
  27. Ten Cate H., Henny C. P., Büller H. R., Ten Cate J. W., Magnani H. N. Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease. Ann Neurol. 1984 Mar;15(3):268–270. doi: 10.1002/ana.410150311. [DOI] [PubMed] [Google Scholar]
  28. Thomson C., Forbes C. D., Prentice C. R. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Mol Med. 1973 Oct;45(4):485–494. doi: 10.1042/cs0450485. [DOI] [PubMed] [Google Scholar]
  29. Turpie A. G., Levine M. N., Hirsh J., Carter C. J., Jay R. M., Powers P. J., Andrew M., Magnani H. N., Hull R. D., Gent M. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet. 1987 Mar 7;1(8532):523–526. doi: 10.1016/s0140-6736(87)90173-5. [DOI] [PubMed] [Google Scholar]
  30. Vitoux J. F., Mathieu J. F., Roncato M., Fiessinger J. N., Aiach M. Heparin-associated thrombocytopenia treatment with low molecular weight heparin. Thromb Haemost. 1986 Feb 28;55(1):37–39. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES